230 related articles for article (PubMed ID: 34540687)
1. Anticancer Effects of I-BET151, an Inhibitor of Bromodomain and Extra-Terminal Domain Proteins.
Lai J; Liu Z; Zhao Y; Ma C; Huang H
Front Oncol; 2021; 11():716830. PubMed ID: 34540687
[TBL] [Abstract][Full Text] [Related]
2. BET bromodomain proteins are required for glioblastoma cell proliferation.
Pastori C; Daniel M; Penas C; Volmar CH; Johnstone AL; Brothers SP; Graham RM; Allen B; Sarkaria JN; Komotar RJ; Wahlestedt C; Ayad NG
Epigenetics; 2014 Apr; 9(4):611-20. PubMed ID: 24496381
[TBL] [Abstract][Full Text] [Related]
3. NF-κB signaling activation via increases in BRD2 and BRD4 confers resistance to the bromodomain inhibitor I-BET151 in U937 cells.
Hishiki K; Akiyama M; Kanegae Y; Ozaki K; Ohta M; Tsuchitani E; Kaito K; Yamada H
Leuk Res; 2018 Nov; 74():57-63. PubMed ID: 30300821
[TBL] [Abstract][Full Text] [Related]
4. The BET bromodomain inhibitor I-BET151 acts downstream of smoothened protein to abrogate the growth of hedgehog protein-driven cancers.
Long J; Li B; Rodriguez-Blanco J; Pastori C; Volmar CH; Wahlestedt C; Capobianco A; Bai F; Pei XH; Ayad NG; Robbins DJ
J Biol Chem; 2014 Dec; 289(51):35494-502. PubMed ID: 25355313
[TBL] [Abstract][Full Text] [Related]
5. I-BET151 suppresses osteoclast formation and inflammatory cytokines secretion by targetting BRD4 in multiple myeloma.
Guo NH; Zheng JF; Zi FM; Cheng J
Biosci Rep; 2019 May; 39(5):. PubMed ID: 30455393
[No Abstract] [Full Text] [Related]
6. The BET bromodomain inhibitor i-BET151 impairs ovarian cancer metastasis and improves antitumor immunity.
Liu A; Fan D; Wang Y
Cell Tissue Res; 2018 Dec; 374(3):577-585. PubMed ID: 30182276
[TBL] [Abstract][Full Text] [Related]
7. Control of NF-kB activity in human melanoma by bromodomain and extra-terminal protein inhibitor I-BET151.
Gallagher SJ; Mijatov B; Gunatilake D; Gowrishankar K; Tiffen J; James W; Jin L; Pupo G; Cullinane C; McArthur GA; Tummino PJ; Rizos H; Hersey P
Pigment Cell Melanoma Res; 2014 Nov; 27(6):1126-37. PubMed ID: 24924589
[TBL] [Abstract][Full Text] [Related]
8. Overexpression of Bromodomain and Extraterminal Domain is Associated with Progression, Metastasis and Unfavorable Outcomes: Highlighting Prognostic and Therapeutic Value of the BET Protein Family in Gastric Cancer.
Fard SS; Kouchaki S; Salimian Z; Sotoudeh M; Mousavi SA; Alimoghaddam K; Ghaffari SH
Anticancer Agents Med Chem; 2023; 23(7):794-806. PubMed ID: 36284375
[TBL] [Abstract][Full Text] [Related]
9. The bromodomain protein inhibitor I-BET151 suppresses expression of inflammatory genes and matrix degrading enzymes in rheumatoid arthritis synovial fibroblasts.
Klein K; Kabala PA; Grabiec AM; Gay RE; Kolling C; Lin LL; Gay S; Tak PP; Prinjha RK; Ospelt C; Reedquist KA
Ann Rheum Dis; 2016 Feb; 75(2):422-9. PubMed ID: 25467295
[TBL] [Abstract][Full Text] [Related]
10. Bromodomain and extra-terminal domain bromodomain inhibition prevents synovial inflammation via blocking IκB kinase-dependent NF-κB activation in rheumatoid fibroblast-like synoviocytes.
Xiao Y; Liang L; Huang M; Qiu Q; Zeng S; Shi M; Zou Y; Ye Y; Yang X; Xu H
Rheumatology (Oxford); 2016 Jan; 55(1):173-84. PubMed ID: 26324948
[TBL] [Abstract][Full Text] [Related]
11. The Bromodomain and Extra-Terminal Domain (BET) Family: Functional Anatomy of BET Paralogous Proteins.
Taniguchi Y
Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27827996
[TBL] [Abstract][Full Text] [Related]
12. BRD4 bimodal binding at promoters and drug-induced displacement at Pol II pause sites associates with I-BET sensitivity.
Khoueiry P; Ward Gahlawat A; Petretich M; Michon AM; Simola D; Lam E; Furlong EE; Benes V; Dawson MA; Prinjha RK; Drewes G; Grandi P
Epigenetics Chromatin; 2019 Jul; 12(1):39. PubMed ID: 31266503
[TBL] [Abstract][Full Text] [Related]
13. The Bromodomain protein BRD4 controls HOTAIR, a long noncoding RNA essential for glioblastoma proliferation.
Pastori C; Kapranov P; Penas C; Peschansky V; Volmar CH; Sarkaria JN; Bregy A; Komotar R; St Laurent G; Ayad NG; Wahlestedt C
Proc Natl Acad Sci U S A; 2015 Jul; 112(27):8326-31. PubMed ID: 26111795
[TBL] [Abstract][Full Text] [Related]
14. Bromodomain and Extra-Terminal (BET) Domain Protein Inhibitors for Solid Tumor Cancers.
Nguyen MV; Loof L; Falchook GS
J Immunother Precis Oncol; 2020 Feb; 3(1):16-22. PubMed ID: 35756176
[TBL] [Abstract][Full Text] [Related]
15. BRD4 regulates self-renewal ability and tumorigenicity of glioma-initiating cells by enrichment in the Notch1 promoter region.
Tao Z; Li X; Wang H; Chen G; Feng Z; Wu Y; Yin H; Zhao G; Deng Z; Zhao C; Li Y; Sun T; Zhou Y
Clin Transl Med; 2020 Oct; 10(6):e181. PubMed ID: 33135348
[TBL] [Abstract][Full Text] [Related]
16. Discovery of novel small molecule induced selective degradation of the bromodomain and extra-terminal (BET) bromodomain protein BRD4 and BRD2 with cellular potencies.
Jiang F; Wei Q; Li H; Li H; Cui Y; Ma Y; Chen H; Cao P; Lu T; Chen Y
Bioorg Med Chem; 2020 Jan; 28(1):115181. PubMed ID: 31767403
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of bromodomain and extraterminal domain reduces growth and invasive characteristics of chemoresistant ovarian carcinoma cells.
Momeny M; Eyvani H; Barghi F; Ghaffari SH; Javadikooshesh S; Hassanvand Jamadi R; Esmaeili F; Alishahi Z; Zaghal A; Bashash D; Samani FS; Ghaffari P; Dehpour AR; Tavangar SM; Alimoghaddam K; Ghavamzadeh A
Anticancer Drugs; 2018 Nov; 29(10):1011-1020. PubMed ID: 30096128
[TBL] [Abstract][Full Text] [Related]
18. I-BET151 inhibits expression of RANKL, OPG, MMP3 and MMP9 in ankylosing spondylitis
Fan J; Zhao J; Shao J; Wei X; Zhu X; Li M
Exp Ther Med; 2017 Nov; 14(5):4602-4606. PubMed ID: 29067128
[TBL] [Abstract][Full Text] [Related]
19. Bromodomain and extra-terminal inhibitors emerge as potential therapeutic avenues for gastrointestinal cancers.
Sun HY; Du ST; Li YY; Deng GT; Zeng FR
World J Gastrointest Oncol; 2022 Jan; 14(1):75-89. PubMed ID: 35116104
[TBL] [Abstract][Full Text] [Related]
20. Targeting Bromodomain and Extra-Terminal (BET) Family Proteins in Castration-Resistant Prostate Cancer (CRPC).
Welti J; Sharp A; Yuan W; Dolling D; Nava Rodrigues D; Figueiredo I; Gil V; Neeb A; Clarke M; Seed G; Crespo M; Sumanasuriya S; Ning J; Knight E; Francis JC; Hughes A; Halsey WS; Paschalis A; Mani RS; Raj GV; Plymate SR; Carreira S; Boysen G; Chinnaiyan AM; Swain A; de Bono JS;
Clin Cancer Res; 2018 Jul; 24(13):3149-3162. PubMed ID: 29555663
[No Abstract] [Full Text] [Related]
[Next] [New Search]
